WT1 and rectum adenocarcinoma: Therefore, we developed a Bi-TCRm-ADC (ESK-1G4-MMAE) against WT1 RMF/HLA-A*02:01 complex and NY-ESO-1 SLL/HLA-A*02:01 complex since the expression profiles of WT1 and NY-ESO-1 in tumor overlap partly, such as in esophageal carcinoma, lung squamous cell carcinoma, and rectum adenocarcinoma (Figure S4).